Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and trial-in-progress updates across the RP1, RP2 and RP3 programs WOBURN, Mass. , May 26, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc.